Unknown

Dataset Information

0

Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders.


ABSTRACT: HIV associated neurocognitive disorders (HAND) are the spectrum of cognitive impairments present in patients infected with human immunodeficiency virus type 1 (HIV-1). The number of patients affected with HAND ranges from 30 to 50% of HIV infected individuals and although the development of combinational antiretroviral therapy (cART) has improved longevity, HAND continues to pose a significant clinical problem as the current standard of care does not alleviate or prevent HAND symptoms. At present, the pathological mechanisms contributing to HAND remain unclear, but evidence suggests that it stems from neuronal injury due to chronic release of neurotoxins, chemokines, viral proteins, and proinflammatory cytokines secreted by HIV-1 activated microglia, macrophages and astrocytes in the central nervous system (CNS). Furthermore, the blood-brain barrier (BBB) not only serves as a route for HIV-1 entry into the brain but also prevents cART therapy from reaching HIV-1 brain reservoirs, and therefore could play an important role in HAND. The goal of this review is to discuss the current data on the epidemiology, pathology and research models of HAND as well as address the potential pharmacological treatment approaches that are being investigated.

SUBMITTER: Omeragic A 

PROVIDER: S-EPMC7350632 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders.

Omeragic Amila A   Kayode Olanre O   Hoque Md Tozammel MT   Bendayan Reina R  

Fluids and barriers of the CNS 20200710 1


HIV associated neurocognitive disorders (HAND) are the spectrum of cognitive impairments present in patients infected with human immunodeficiency virus type 1 (HIV-1). The number of patients affected with HAND ranges from 30 to 50% of HIV infected individuals and although the development of combinational antiretroviral therapy (cART) has improved longevity, HAND continues to pose a significant clinical problem as the current standard of care does not alleviate or prevent HAND symptoms. At presen  ...[more]

Similar Datasets

2009-08-05 | E-GEOD-17383 | biostudies-arrayexpress
| S-EPMC2690857 | biostudies-other
| S-EPMC10531836 | biostudies-literature
2009-08-05 | GSE17383 | GEO
| S-EPMC4313542 | biostudies-literature
| S-EPMC6454832 | biostudies-literature
| S-EPMC8155894 | biostudies-literature
| S-EPMC4993448 | biostudies-literature
| S-EPMC9294194 | biostudies-literature
| S-EPMC9305687 | biostudies-literature